KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 20.76%.

  • Alnylam Pharmaceuticals' EBITDA Margin rose 410700.0% to 20.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.76%, marking a year-over-year increase of 172600.0%. This contributed to the annual value of 12.87% for FY2024, which is 100500.0% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its EBITDA Margin stood at 20.76% for Q3 2025, which was up 410700.0% from 7.59% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' EBITDA Margin's 5-year high stood at 20.76% during Q3 2025, with a 5-year trough of 201.59% in Q1 2025.
  • Its 5-year average for EBITDA Margin is 65.72%, with a median of 62.19% in 2022.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' EBITDA Margin soared by 1744900bps in 2023, and later plummeted by -1875200bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBITDA Margin stood at 99.6% in 2021, then soared by 38bps to 62.19% in 2022, then skyrocketed by 53bps to 29.32% in 2023, then surged by 46bps to 15.76% in 2024, then surged by 232bps to 20.76% in 2025.
  • Its EBITDA Margin stands at 20.76% for Q3 2025, versus 7.59% for Q2 2025 and 201.59% for Q1 2025.